Published: Wed, September 20, 2017
Economy | By Melissa Porter

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) closed with a change of 0

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) closed with a change of 0

The stock of Walgreens Boots Alliance Inc (NASDAQ:WBA) earned "Buy" rating by Needham on Monday, July 17. Also, the current price highlights a discount of 73.91% to analysts' high consensus price target.

WBA has been the subject of several recent research reports.

LYB's price to sales ratio for trailing twelve months is 1.18 and price to book ratio for most recent quarter is 5.58, whereas price to cash per share for the most recent quarter is 18.66. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25* countries and employ more than 400,000* people.

"We are confident in the path ahead and look forward to working together to shape the future of health care and deliver on the full potential these stores bring to our network", Walgreens Executive Vice Chairman and CEO Stefano Pessina said in a press release. The rating was maintained by Jefferies on Tuesday, September 5 with "Buy". Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company's stock. The firm has "Buy" rating given on Friday, April 7 by Guggenheim. The overall volume in the last trading session was 5.8 million shares. The company has its outstanding shares of 840.06M. The stock appeared $88.00 above its 52-week highs and is up 0.39% for the last five trades.

The RSI is most typically used on a 14-day timeframe, measured on a scale from 0 to 100, with high and low levels marked at 70 and 30, respectively. The company has market cap of $3.24 billion.

In October 2016 Walgreens Boots Alliance received the United Nations Foundation Global Leadership Award for its commitment to the UN's Sustainable Development Goals. The business's quarterly revenue was up 2.1% compared to the same quarter a year ago.

EPS Estimate for the next Quarter is 1.21. The average analysts gave this company a mean recommendation of 2.80. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has "Buy" rating given on Tuesday, August 1 by Oppenheimer. This is a positive change from Walgreens Boots Alliance's previous quarterly dividend of $0.38.

The deal should not have a significant impact on Walgreens' adjusted earnings for the fiscal year ending August 31, 2018, the company added, and it expects annual synergies from the new transaction of more than $300 million. During the same period past year, the company earned $1.18 earnings per share. The Beta for the stock stands at 1.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Array BioPharma Inc. The disclosure for this purchase can be found here.

A number of large investors have recently added to or reduced their stakes in the business. During last 3 month period, 3.48% of total institutional ownership has changed in the company shares. TIAA CREF Investment Management LLC now owns 5,269,500 shares of the pharmacy operator's stock worth $437,632,000 after purchasing an additional 962,959 shares during the period. This buyback authorization authorizes the pharmacy operator to purchase up to 5.9% of its stock through open market purchases. Franklin Resources Inc. increased its holdings in Walgreens Boots Alliance by 24.7% in the 2nd quarter.

Zayo Group Holdings, Inc.

Like this: